Equities

Global Bioenergies SA

Global Bioenergies SA

Actions
EnergyAlternative Energy
  • Price (EUR)1.83
  • Today's Change0.00 / 0.00%
  • Shares traded4.51k
  • 1 Year change-23.11%
  • Beta1.3995
Data delayed at least 15 minutes, as of May 17 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Global Bioenergies SA is a France-based company that specializes in the development of a process to produce isobutene biologically from renewable resources. Isobutene, a hydrocarbon, can be converted into fuels such as isooctane, as well as into various materials (synthetic rubber, organic glass, plastics). The process developed by Global Bioenergies SA is based on the design of an artificial metabolic pathway comprising several enzymes catalyzing reactions not observed in nature. Six patent applications have been filed by the Company. The first two applications covering the key steps of the bio-production of isobutene and other olefins have already been published. It distributes butane and propane containing bio-isobutene, in a e partnership with Global Bioenergies. It operates through Syngip.

  • Revenue in EUR (TTM)3.25m
  • Net income in EUR-8.66m
  • Incorporated2008
  • Employees46.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
SMAIO SA7.62m1.06m17.99m37.0016.881.667.562.360.20380.20381.462.070.56240.187117.23206,027.607.81-7.8710.24-19.7696.9596.0413.89-22.482.5411.070.1991--212.18114.99-62.80------
Phaxiam Therapeutics SA1.33m-23.49m18.56m51.00--0.7246--14.00-5.56-5.560.31394.220.0273--14.8226,000.00-48.37-50.69-66.94-66.25-----1,771.42-1,009.09---70.210.3412---80.05-21.50-10,201.75---56.68--
NicOx SA3.57m-17.36m18.61m11.00--0.4054--5.21-0.3721-0.37210.07530.91280.0394--1.83324,909.10-19.13-19.22-21.35-20.78-----485.70-370.14----0.3172---54.787.2536.57---13.35--
Nfl Biosciences SAS0.00-3.48m20.96m3.00--5.32-----0.5396-0.53960.000.40970.00----0.00-80.79---125.59--------------0.0228-------149.78------
Oncodesign Precision Medicine Opm SA1.07m-8.09m23.65m22.00--5.86--22.06-0.4863-0.48630.06450.22190.0613--1.3948,735.00-46.23---63.87--130.48---754.61------0.7052---86.57---3,399.73------
Advicenne SA2.37m-10.39m26.13m25.00------11.04-1.03-1.030.2342-1.400.19386.101.9494,680.00-85.09-46.00-178.65-61.82-204.18-441.10-438.99-597.560.8356-6.224.33---12.3233.267.70--26.86--
Predilife SA317.79k-4.22m26.41m19.00------83.12-1.14-1.140.0858-1.060.0695--2.0517,030.55-92.43-89.36-129.39-123.8197.2583.94-1,329.21-1,901.22---6.232.20--10.1179.85-15.58---18.51--
Poxel SA1.55m-44.24m29.68m30.00------19.20-1.44-1.440.0507-1.220.0597--5.4230,920.00-170.71-31.97-432.50-55.940.1294---2,861.58-101.47---4.0811.28---94.97-33.77-32.13---8.49--
Global Bioenergies SA3.25m-8.66m33.19m46.00--3.19--10.22-0.4797-0.47970.18020.57430.16325.2165.6270,638.05-43.47-43.66-64.54-82.47-153.20-948.35-266.41-1,331.363.54--0.2626--365.8336.2527.78---19.49--
Fermentalg SA4.06m-14.15m33.24m62.00--1.02--8.19-0.3176-0.31760.09170.60330.07530.5333.3565,451.61-24.63-21.94-26.79-24.7113.2114.73-327.08-248.953.53-60.940.3323---46.9475.18-43.29---10.93--
Abionyx Pharma SA4.64m-3.52m35.38m61.00--4.43--7.63-0.121-0.1210.15810.2460.302721.864.2076,694.22-22.95-18.82-32.52-28.8713.3214.32-75.82-128.541.70--0.2997---11.6592.8416.36--41.40--
Groupe Berkem SA51.94m367.00k38.73m200.00105.571.398.710.74570.02070.02072.921.57------259,720.00--------55.32--0.7065--0.89881.360.5798--0.733--123.42------
genOway SA18.63m1.59m39.88m124.0023.712.349.942.140.18140.18142.121.840.58130.38812.50142,180.804.98-0.56156.72-0.805897.6193.728.56-1.122.1017.420.3344--21.6411.57341.09-16.63-18.02--
Gensight Biologics SA1.27m-26.22m40.14m16.00------31.68-0.5427-0.54270.0269-0.47260.0723--2,534.0079,187.50-149.52-79.44---144.54-----2,069.53-1,036.27---------50.93--5.09---58.28--
Biosynex SA93.05m-13.79m41.54m560.00------0.4464-1.94-1.94----------248,141.30--25.60--33.9025.2251.82-13.1520.26---4.45--14.72-48.6145.12-84.99118.26----
AbL Diagnostics SA11.19m1.20m48.99m19.005.077.30161.454.380.59970.59975.580.41651.18--5.21588,990.5012.678.9926.0910.7735.7638.2910.7531.171.28--0.310.00--67.89328.77------
Data as of May 17 2024. Currency figures normalised to Global Bioenergies SA's reporting currency: Euro EUR

Institutional shareholders

4.65%Per cent of shares held by top holders
HolderShares% Held
OFI Invest Asset Management SAas of 29 Feb 2024434.00k2.39%
La Fran�aise Asset Management SASas of 31 Jan 2024183.52k1.01%
UBS LA MAISON de Gestionas of 30 Dec 2022126.97k0.70%
Friedland Gestion SASas of 31 Jan 202458.59k0.32%
Uzes Gestion SAas of 26 Apr 202440.00k0.22%
Financi�re Arbevel SAas of 30 Dec 20220.000.00%
More ▼
Data from 31 Jan 2024 - 30 Apr 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.